Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Merck
Moodys
Medtronic
McKinsey

Last Updated: May 26, 2022

VIAGRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Viagra, and when can generic versions of Viagra launch?

Viagra is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in VIAGRA is sildenafil citrate. There are twenty drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

Drug patent expirations by year for VIAGRA
Drug Prices for VIAGRA

See drug prices for VIAGRA

Drug Sales Revenue Trends for VIAGRA

See drug sales revenues for VIAGRA

Recent Clinical Trials for VIAGRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cairo UniversityPhase 1
The University of Texas Medical Branch, GalvestonPhase 2
Sohag UniversityPhase 1/Phase 2

See all VIAGRA clinical trials

Paragraph IV (Patent) Challenges for VIAGRA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIAGRA Tablets sildenafil citrate 25 mg and 50 mg 020895 1 2004-11-19
VIAGRA Tablets sildenafil citrate 100 mg 020895 1 2004-10-25

US Patents and Regulatory Information for VIAGRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIAGRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998 See Plans and Pricing See Plans and Pricing
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 See Plans and Pricing See Plans and Pricing
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VIAGRA

See the table below for patents covering VIAGRA around the world.

Country Patent Number Title Estimated Expiration
Hungary 218945 Pirazolo-pirimidinon-származékok és a vegyületeket tartalmazó gyógyászati készítmények, eljárás a vegyületek és a készítmények előállítására (PYRAZOLO PYRIMIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESS FOR PRODUCING THE COMPOUNDS AND THE COMPOSITIONS) See Plans and Pricing
Hungary 211646 See Plans and Pricing
Brazil 9102560 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VIAGRA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0463756 C990005 Netherlands See Plans and Pricing PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756 5/1999 Austria See Plans and Pricing PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
0463756 300048 Netherlands See Plans and Pricing PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
AstraZeneca
Baxter
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.